The company’s clinical laboratory offers plasma-based fungal tests with results reported in under 24 hours.
Zepto Life Technology announced that its clinical laboratory has been accredited by the College of American Pathologists (CAP).
The laboratory offers the FungiFlex menu of targeted plasma cell-free DNA tests to aid in diagnosing invasive fungal infections. Results are reported in less than 24 hours after sample receipt, according to the company.
“Behind every specimen is a patient waiting for answers. The quality of our work matters to that patient and the clinicians caring for them. CAP accreditation recognizes the standards our laboratory team works hard to uphold every day,” says Hannah Zhang, CEO of Zepto Life Technology, in a release.
Targeting Invasive Fungal Infections
Invasive fungal infections are particularly challenging in patients with weakened immune systems, including transplant recipients and people with hematologic malignancies. FungiFlex detects fungal DNA circulating in plasma, providing organism-level information from a standard blood draw to complement other clinical and diagnostic findings, according to the company.
The test menu includes:
- The Mold Panel, which detects 14 clinically important mold species.
- Targeted Pneumocystis jirovecii testing.
- The Mold Plus Panel, which combines both.
All are offered as laboratory-developed tests through Zepto’s CLIA-certified reference laboratory.
Zepto describes itself as a molecular diagnostics company bringing plasma cell-free DNA liquid biopsy testing into infectious disease. The company is also advancing the Zepto MDx platform, which is intended to bring sample-to-result liquid biopsy testing directly into hospital and clinical microbiology laboratories.
CAP accreditation is widely recognized as a benchmark for laboratory quality, reflecting standards across testing operations, personnel, equipment, facilities, safety, and quality systems, the company says.